Sortis (Atorvastatin)

Sortis, containing the active ingredient atorvastatin, is a major brand of cholesterol-lowering medication used to prevent cardiovascular disease. It was originally developed by the pharmaceutical team at Parke-Davis, which later became part of Warner-Lambert. The drug gained global prominence following its approval in the late 1990s as one of the most effective statins on the market.

Today, the brand is part of the Viatris portfolio. Viatris was formed through a massive merger between Mylan and Pfizer's Upjohn division, a move intended to consolidate legacy pharmaceutical brands under a specialized global healthcare banner. While Pfizer maintains a historical connection to the product, Viatris manages the manufacturing and global distribution for Sortis in many European and international markets.

Manufacturing for Sortis is highly standardized across global facilities. Major production hubs are located in Freiburg, Germany, and Dublin, Ireland. These facilities ensure that the medication meets strict international safety and efficacy standards before being distributed to pharmacies worldwide.